Laise Mara Oliveira Miranda1, Lívia da Cunha Agostini2, Wanderson Geraldo de Lima3, Fernanda Caetano Camini4, Daniela Caldeira Costa5. 1. Programa de Pós-graduação em Saúde e Nutrição, Escola de Nutrição, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais 35400-000, Brazil. 2. Escola de Farmácia, Universidade Federal de Ouro Preto. Ouro Preto, Minas Gerais 35400-000, Brazil. 3. Laboratório de Morfopatologia, Departamento de Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto 35400-000, Brazil. 4. Programa de Pós-graduação em Ciências Biológicas, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto. Ouro Preto 35400-000, Brazil. 5. Laboratório de Bioquímica Metabólica, Departamento de Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto 35400-000, Brazil.
Abstract
OBJECTIVE: To evaluate the efficiency of silymarin (SMN) in modulating metabolic parameters and redox status in rats with type 1 diabetes mellitus (T1DM). METHODS: Diabetes was induced by intraperitoneal injection of alloxan. The diabetic rats were administered with SMN at doses of 50 and 100 mg/kg body weight/d for 30 consecutive days. The rats were divided into the following four groups: vehicle control, diabetic (alloxan-treated), DS50 (alloxan + 50 mg/kg body weight/d of SMN), and DS100 (alloxan + 100 mg/kg body weight/d of SMN) groups. The bodyweight and food and water intake were evaluated. After 30 d, the animals were euthanized and the blood was collected for measuring the serum levels of glucose, triacylglycerol (TAG), urea, and creatinine. The liver and pancreas were collected for measuring the activities of superoxide dismutase (SOD) and catalase (CAT), and the levels of carbonylated protein (PC). The pancreas sample was also used for histological analysis. RESULTS: SMN reduced hepatic ( P < 0.001) and pancreatic ( P < 0.001) protein damage and creatinine levels ( P = 0.0141) in addition to decreasing food ( P < 0.001) and water intake ( P < 0.001). However, treatment with SMN did not improve beta-cell function or decrease blood glucose levels in diabetic rats. CONCLUSION: SMN improved polyphagia and polydipsia, renal function, and protected the liver and pancreas against protein damage without affecting hyperglycemia in diabetic animals.
OBJECTIVE: To evaluate the efficiency of silymarin (SMN) in modulating metabolic parameters and redox status in rats with type 1 diabetes mellitus (T1DM). METHODS: Diabetes was induced by intraperitoneal injection of alloxan. The diabetic rats were administered with SMN at doses of 50 and 100 mg/kg body weight/d for 30 consecutive days. The rats were divided into the following four groups: vehicle control, diabetic (alloxan-treated), DS50 (alloxan + 50 mg/kg body weight/d of SMN), and DS100 (alloxan + 100 mg/kg body weight/d of SMN) groups. The bodyweight and food and water intake were evaluated. After 30 d, the animals were euthanized and the blood was collected for measuring the serum levels of glucose, triacylglycerol (TAG), urea, and creatinine. The liver and pancreas were collected for measuring the activities of superoxide dismutase (SOD) and catalase (CAT), and the levels of carbonylated protein (PC). The pancreas sample was also used for histological analysis. RESULTS: SMN reduced hepatic ( P < 0.001) and pancreatic ( P < 0.001) protein damage and creatinine levels ( P = 0.0141) in addition to decreasing food ( P < 0.001) and water intake ( P < 0.001). However, treatment with SMN did not improve beta-cell function or decrease blood glucose levels in diabetic rats. CONCLUSION: SMN improved polyphagia and polydipsia, renal function, and protected the liver and pancreas against protein damage without affecting hyperglycemia in diabetic animals.
Authors: Nikolaos P E Kadoglou; Chrystalla Panayiotou; Michail Vardas; Nikolaos Balaskas; Nikolaos G Kostomitsopoulos; Alexandra K Tsaroucha; Georgia Valsami Journal: Pharmaceuticals (Basel) Date: 2022-04-27
Authors: Laura Hurtado-Navarro; Diego Angosto-Bazarra; Pablo Pelegrín; Alberto Baroja-Mazo; Santiago Cuevas Journal: Antioxidants (Basel) Date: 2022-04-28